Dental care provider Delta Dental of Michigan and Ohio has led a $10m extension to a series C round for US-based healthcare computer vision technology developer Gauss that now totals $30m.
The corporate invested through subsidiary 4100 Group and was joined by SoftBank Ventures Asia – part of telecommunications group SoftBank – as well as health systems Northwell Health, OSF Healthcare and Providence Health and Services, in addition to venture capital firm Polaris Partners.
Gauss has created a computer vision system that identifies surgical and obstetric haemorrhages in real time and alerts clinicians.
The series C proceeds will support clinical testing of an at-home diagnostics test for covid-19 the company is developing with point-of-care diagnostic test provider Cellex. Scott Lancaster, managing director of private market investments for 4100 Group, is joining its board of directors.
All the participants in the extension also contributed to the round’s $20m first tranche in late 2018, with OSF, Providence and Polaris taking part through subsidiaries OSF Ventures, Providence Ventures and LS Polaris Innovation Fund.
The first close also featured care providers Memorial Hermann Health System, UNC/Rex Healthcare, Orlando Health, Spectrum Health and Mount Sinai Health System, the last four through Rex Health Ventures, Orlando Health Ventures, Spectrum Health Ventures and Mount Sinai Ventures.
Gauss has now raised $54.6m since it was founded in 2011, including $12.6m in series B funding from investors including Summation Health Ventures, which was formed by healthcare providers Cedars-Sinai Health System and MemorialCare Health System, in 2016.
Stanford-StartX Fund, Promus Ventures, LifeForce Ventures and Jump Capital filled out the series B round, which was preceded by a $12m series A led by Promus Ventures and backed by Summation Health Ventures and LifeForce Ventures the year before. Its earlier investors include Taube Investment Partners.
